Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M890Revenue $M81.4Net Margin (%)-196.7Z-Score-1.6
Enterprise Value $M704EPS $-0.1Operating Margin %-305.4F-Score7
P/E(ttm))0Cash Flow Per Share $-0.6Pre-tax Margin (%)-138.8Higher ROA y-yY
Price/Book7.010-y EBITDA Growth Rate %-31.4Quick Ratio4.0Cash flow > EarningsY
Price/Sales10.35-y EBITDA Growth Rate %-60.9Current Ratio4.1Lower Leverage y-yY
Price/Cash Flow0y-y EBITDA Growth Rate %0ROA % (ttm)-18.1Higher Current Ratio y-yY
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)-52.4Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M220ROI % (ttm)-11.9Gross Margin Increase y-yY

Gurus Latest Trades with ARNA

Number of guru portfolios checked: 56. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
Current Price Change from Average Comment Current Shares
ARNAMario Gabelli 2011-03-31 Sold Out $1.41 - $2.16
$ 4135%Sold Out0
ARNAMario Gabelli 2010-12-31 Buy $1.27 - $2.38
$ 4153%New holding, 13000 sh.13,000
ARNAGeorge Soros 2008-06-30 Sold Out -0.01%$4.67 - $6.92
$ 4-27%Sold Out0
ARNAGeorge Soros 2006-12-31 Sold Out -0.05%$12.95 - $17.39
$ 4-73%Sold Out0
ARNAGeorge Soros 2006-09-30 Add0.04%$9.23 - $12.22
$ 4-63%Add 266%55,000
ARNAGeorge Soros 2006-06-30 Buy 0.02%$10.54 - $15.58
$ 4-70%New holding, 15000 sh.15,000
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

ARNA is held by these Gurus:

Premium Most recent portfolio changes are included for Premium Members only!

ARNA: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
LIEF JACKChairman, President and CEO 2014-07-01Sell223,525$5.85-31.62 view
BELCHER DONALD DDirector 2014-06-27Sell2,473$5.85-31.62 view
SPECTOR STEVEN WEVP, General Counsel & Sec 2014-05-12Sell45,000$7.05-43.26 view
BELCHER DONALD DDirector 2014-05-06Sell4,176$7-42.86 view
HIXSON HARRY F JRDirector 2014-04-22Sell36,900$6.31-36.61 view
Nova Tina SusanDirector 2014-04-14Sell35,000$6.22-35.69 view
SHANAHAN WILLIAM R JRSVP & Chief Medical Officer 2014-04-01Sell60,000$6.37-37.21 view
BELCHER DONALD DDirector 2014-04-01Sell1,905$6.45-37.98 view
SPECTOR STEVEN WEVP, General Counsel & Sec 2014-03-04Sell25,000$7.01-42.94 view
LIEF JACKChairman, President and CEO 2014-01-17Sell100,000$7.81-48.78 view

Press Releases about ARNA :

    Quarterly/Annual Reports about ARNA:

    News about ARNA:

    Articles On GuruFocus.com
    Revisiting Arena, Orexigen, And VIVUS: Shareholders Can Recoup Their Losses By Invest In MannKind Aug 19 2014 
    (ARNA) Initiated with a Buy, (ICLD, FONR) Strong Performance on Financial Results Nov 16 2013 
    comment on ARNA Mar 15 2013 
    comment on ARNA Mar 02 2013 
    Arena Facing Increased Pressure from Peers Apr 23 2012 
    Arena Could Dip If Lorcaserin Fails Again Apr 22 2012 
    Vivus Could Rocket on Success of Qnexa Apr 13 2012 
    These 4 Biotech Stocks Are a Buy Now Feb 08 2012 

    More From Other Websites
    Zafgen Aims Obesity Drug At Rare, Deadly Disease Oct 02 2014
    [video] Zafgen CEO: 2015 Will Be Data Rich Year for Obesity Treatment Sep 30 2014
    Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference Sep 22 2014
    Arena Pharmaceuticals, Inc. (ARNA) Jumps: Stock Rises 9.5% Sep 19 2014
    Doc Offers Glimpse Into Arena Pharma Weight-Loss Combination Therapy Sep 16 2014
    [video] Orexigen drops in spite of FDA approval Sep 11 2014
    U.S. FDA panel: Novo Nordisk's liraglutide safe/effective for obesity Sep 11 2014
    Orexigen's Obesity Pill is Approved and Stock Falls. Don't be Surprised Sep 11 2014
    Pharmalot, Pharmalittle: We're Reading About Orexigen, Allergan and Lots More!! Sep 11 2014
    Lorcaserin HCl Data to be Presented at the American Society of Bariatric Physicians' 64th Annual... Sep 10 2014
    FDA staff: Novo Nordisk drug liraglutide effective for obesity Sep 09 2014
    Arena Pharmaceuticals' APD811 Gets Orphan Drug Status Sep 03 2014
    Arena Pharmaceuticals' APD811 Granted Orphan Drug Status for Pulmonary Arterial Hypertension Sep 02 2014
    [video] Obesity treatment sales fall short Aug 18 2014
    ARENA PHARMACEUTICALS INC Financials Aug 15 2014
    ARENA PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report Aug 06 2014
    Arena Pharmaceuticals Falls on Wider-than-Expected Q2 Loss Aug 04 2014
    ARENA PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition,... Aug 01 2014
    Q2 2014 Arena Pharmaceuticals Earnings Release - After Market Close Aug 01 2014
    Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results Aug 01 2014

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial